Centiva Capital, LP Bio N Tech Se Transaction History

Centiva Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$122.57 - $153.67 $5,147 - $6,454	42 Added 28.19%	191 $23,000
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $17,646 - $27,721	149 New	149 $22,000
Q2 2022 Aug 17, 2022	SELL	$123.25 - $186.24 $8.32 Million - $12.6 Million	-67,500 Reduced 98.9%	749 $112,000
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $7.39 Million - $11.2 Million	59,976 Added 724.96%	68,249 $10.2 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $591,102 - $1.09 Million	4,682 Added 130.38%	8,273 $1.41 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $286,181 - $478,888	-1,321 Reduced 26.89%	3,591 $926,000
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $800,861 - $1.74 Million	3,889 Added 380.16%	4,912 $1.34 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $115,926 - $247,044	1,023 New	1,023 $229,000

328

40.6M

845K

1.23M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.9B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.